The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.
Zacks Investment Research on MSN
CAPR updates FDA on Deramiocel BLA, plans HOPE-3 CSR filing in February
Capricor Therapeutics CAPR recently provided a regulatory update on its Biologics License Application (BLA) for Deramiocel, ...
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it has submitted a Biologics ...
Valneva has made the decision to withdraw the Biologics License Application for its chikungunya vaccine Ixchiq®.
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results